D
Replimune Group, Inc. REPL
$11.66 -$0.205-1.73%
Recommendation
Sell
Prev Close
$11.86
Volume
312,000
Avg Vol (90D)
805,169
Market Cap
$913.40M
Dividend & Yield
--
52-Week Range
$4.92 - $17.00
P/E (TTM)
--
EPS (TTM)
-$3.27
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Replimune Group (NASDAQ:REPL) Shares Up 6.4% - Still a Buy?
3/13/2025 - MarketBeat
Replimune Group (REPL, $11.44) RSI Indicator left the oversold zone on March 11, 2025
3/12/2025 - Tickeron - Stocks
Replimune Group (REPL, $11.51) RSI Indicator left the oversold zone on March 07, 2025
3/8/2025 - Tickeron - Stocks
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/7/2025 - Globe Newswire
Replimune Group (REPL, $12.12) price may climb as it broke lower Bollinger Band on Mar 03, 2025
3/4/2025 - Tickeron - Stocks
Replimune Group (REPL, $12.68) Stochastic Oscillator left the oversold zone on February 28, 2025
3/1/2025 - Tickeron - Stocks
Replimune Group (REPL, $12.64) entered Downtrend as Momentum indicator drops below 0 level on Feb 27, 2025
2/28/2025 - Tickeron - Stocks
Replimune Group (REPL, $12.64) price may climb as it broke lower Bollinger Band on Feb 27, 2025
2/28/2025 - Tickeron - Stocks
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock
2/26/2025 - MarketBeat
Replimune Group (REPL, $13.49) entered Uptrend as Momentum indicator ascends above 0 level on Feb 25, 2025
2/26/2025 - Tickeron - Stocks
Replimune Group (NASDAQ:REPL) Stock Price Up 6.1% - Still a Buy?
2/22/2025 - Ticker Report
Replimune Group (NASDAQ:REPL) Shares Up 6.1% - Still a Buy?
2/21/2025 - MarketBeat
Replimune Group (REPL, $14.31) entered Uptrend as Momentum indicator ascends above 0 level on Feb 20, 2025
2/21/2025 - Tickeron - Technical Analysis
Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by Brokerages
2/20/2025 - Ticker Report
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages
2/20/2025 - MarketBeat
Replimune Group (REPL, $13.78) entered Downtrend as Momentum indicator drops below 0 level on Feb 19, 2025
2/20/2025 - Tickeron - Stocks
Replimune Group (REPL, $14.03) Moving Average Convergence Divergence (MACD) Histogram turned negative on February 18, 2025
2/19/2025 - Tickeron - Stocks
Possible Bearish Signals With Replimune Group Insiders Disposing Stock
2/17/2025 - Simply Wall St
FY2025 EPS Estimates for Replimune Group Lowered by Wedbush
2/17/2025 - MarketBeat
Leerink Partnrs Predicts Weaker Earnings for Replimune Group
2/17/2025 - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Short Interest Up 16.7% in January
2/17/2025 - MarketBeat
Replimune Group (REPL, $14.1) Moving Average Convergence Divergence (MACD) Histogram turned positive on February 14, 2025
2/15/2025 - Tickeron - Stocks
Replimune Group (REPL, $14.1) Stochastic Oscillator left the overbought zone on February 14, 2025
2/15/2025 - Tickeron - Stocks
Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00
2/14/2025 - MarketBeat
Replimune Group (REPL, $14.29) entered Uptrend as Momentum indicator ascends above 0 level on Feb 13, 2025
2/14/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$236.25M
EBIT (TTM)
-$239.17M
Net Income (TTM)
-$228.24M
Balance Sheet
Total Assets (Q)
$603.63M
Total Debt (Q)
$76.04M
Total Liabilities (Q)
$121.25M
Book Value Per Share (Q)
$6.26
Cash Flow
Cash from Operations (TTM)
-$184.69M
Cash from Investing (TTM)
$7.11M
Cash from Financing (TTM)
$252.40M
Net Change in Cash (TTM)
$74.64M
Filings
Filing Date
Wednesday, February 12, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.50
7-Day Total Return
-5.17%
30-Day Total Return
-14.43%
60-Day Total Return
-7.13%
90-Day Total Return
-0.89%
Year to Date Total Return
-7.21%
1-Year Total Return
31.84%
2-Year Total Return
-41.31%
3-Year Total Return
-24.86%
5-Year Total Return
14.21%
52-week Low
May 29, 2024 - $4.92
52-week High
Nov 22, 2024 - $17.00
Valuation
Market Cap
$913.40M - Small Cap
Enterprise Value
$452.90M
Price/Sales (TTM)
--
Price/Book (Q)
1.89
Dividends and Shares
Shares Outstanding
77.01M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.replimune.com
Phone Number
781 222 9600
Address
500 Unicorn Park Drive
Woburn, MA 01801
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic... more
NASDAQ 03/14/2025 4:00PM Eastern Quotes delayed
Weiss Ratings